Development of a credible 3D-QSAR CoMSIA model and docking studies for a series of triazoles and tetrazoles containing 11β-HSD1 inhibitors

References

• World Health Organization, Diabetes, Factsheet no. 312 (2015). Available at http://www.who.int/mediacentre/factsheets/fs312/en/ (accessed 11.01.2016).
   Google Scholar
• A. Kapur and A.D. Harries, The double burden of diabetes and tuberculosis – Public health implications, Diabetes Res. Clin. Pract. 101 (2013), pp. 10–19.
   PubMed Web of Science ®Google Scholar
• C.M. Sena, C.F. Bento, P. Pereira, and R. Seica, Diabetes mellitus: New challenges and innovative therapies, EPMA J. 1 (2010), pp. 138–163.
   PubMedGoogle Scholar
• C. Fotsch, M.D. Bartberger, E.A. Bercot, M. Chen, R. Cupples, M. Emery, J. Fretland, A. Guram, C. Hale, N. Han, D. Hickman, R.W. Hungate, M. Hayashi, R. Komorowski, Q. Liu, G. Matsumoto, D.J.S. Jean, S. Ursu, M. Veniant, G. Xu, Q. Ye, C. Yuan, J. Zhang, X. Zhang, H. Tu, and M. Wang, Further studies with the 2-amino-1,3-thiazol-4(5H)-one class of 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: Reducing pregnane X receptor activity and exploring activity in a monkey pharmacodynamic model, J. Med. Chem. 51 (2008), pp. 7953–7967.
   PubMed Web of Science ®Google Scholar
• Z. Xu, C.M. Tice, W. Zhao, S. Cacatian, Y. Ye, S.B. Singh, P. Lindblom, B.M. McKeever, P.M. Krosky, B.A. Kruk, J. Berbaum, R.K. Harrison, J.A. Johnson, Y. Bukhtiyarov, R. Panemangalore, B.B. Scott, Y. Zhao, J.G. Bruno, J. Togias, J. Guo, R. Guo, P.J. Carroll, G.M. McGeehan, L. Zhuang, W. He, and D.A. Claremon, Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11β-hydroxysteroid dehydrogenase type 1, J. Med. Chem. 54 (2011), pp. 6050–6062.
   PubMed Web of Science ®Google Scholar
• G. Hollis and R. Huber, 11β-Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus, Diabetes Obes. Metab. 13 (2011), pp. 1–6.
   PubMed Web of Science ®Google Scholar
• S.P. Webster, M. Binnie, K.M.M. McConnell, K. Sooy, P. Ward, M.F. Greaney, A. Vinter, T.D. Pallin, H.J. Dyke, M.I.A. Gill, I. Warner, J.R. Seckl, and B.R. Walker, Modulation of 11beta-hydroxysteroid dehydrogenase type 1 activity by 1,5-substituted 1H-tetrazoles, Bioorg. Med. Chem. Lett. 20 (2010), pp. 3265–3271.
   PubMed Web of Science ®Google Scholar
• Y. Rew, D.L. McMinn, Z. Wang, X. He, R.W. Hungate, J.C. Jaen, A. Sudom, D. Sun, H. Tu, S. Ursu, E. Villemure, N.P.C. Walker, X. Yan, Q. Ye, and J.P. Powers, Discovery and optimization of piperidyl benzamide derivatives as a novel class of 11beta-HSD1 inhibitors, Bioorg. Med. Chem. Lett. 19 (2009), pp. 1797–1801.
   PubMed Web of Science ®Google Scholar
• N. Vicker, X. Sua, D. Ganeshapillai, A. Smith, A. Purohit, M.J. Reed, and B.V.L. Potter, Novel non-steroidal inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1, J. Steroid. Biochem. Mol. Biol. 104 (2007), pp. 123–129.
   PubMed Web of Science ®Google Scholar
• J.S. Scott, S.S. Bowker, J. deSchoolmeester, S. Gerhardt, D. Hargreaves, E. Kilgour, A. Lloyd, R.M. Mayers, W. McCoull, N.J. Newcombe, D. Ogg, M.J. Packer, A. Rees, J. Revill, P. Schofield, N. Selmi, J.G. Swales, and P.R.O. Whittamore, Discovery of a potent, selective, and orally bioavailable acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor: Discovery of 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid (AZD4017), J. Med. Chem. 55 (2012), pp. 5951−5964.
   PubMed Web of Science ®Google Scholar
• Y. Kotelevtsev, R.W. Brown, S. Fleming, C. Kenyon, C.R.W. Edwards, J.R. Seckl, and J.J. Mullins, Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2, J. Clin. Invest. 103 (1999), pp. 683–689.
   PubMed Web of Science ®Google Scholar
• J. Xiang, M. Ipek, V. Suri, M. Tam, Y. Xing, N. Huang, Y. Zhang, J. Tobin, T.S. Mansoura, and J. McKew, beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action, Bioorg. Med. Chem. 15 (2007), pp. 4396–4405.
   PubMed Web of Science ®Google Scholar
• D. Sun, Z. Wang, Y. Di, J.C. Jaen, M. Labelle, J. Ma, S. Miao, A. Sudom, L. Tang, C.S. Tomooka, H. Tu, S. Ursu, N. Walker, X. Yan, Q. Ye, and J.P. Powers, Discovery and initial SAR of arylsulfonylpiperazine inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), Bioorg Med. Chem. Lett. 18 (2008), pp. 3513–3516.
   PubMed Web of Science ®Google Scholar
• S.C. Wu, D. Yoon, J. Chin, K. Kirk, R. Seethala, R. Golla, B. He, T. Harrity, L.K. Kunselman, N.N. Morgan, R.P. Ponticiello, J.R. Taylor, R. Zebo, T.W. Harper, W. Li, M. Wang, L. Zhang, B.G. Sleczka, A. Nayeem, S. Sheriff, D.M. Camac, P.E. Morin, J.G. Everlof, Y. Li, C.A. Ferraro, K. Kieltyka, W. Shou, M.B. Vath, T.A. Zvyaga, D.A. Gordon, and J.A. Robl, Discovery of 3-hydroxy-4-cyano-isoquinolines as novel, potent, and selective inhibitors of human 11β-hydroxydehydrogenase 1 (11β-HSD1), Bioorg. Med. Chem. Lett. 21 (2011), pp. 6693–6698.
   PubMed Web of Science ®Google Scholar
• Y. Ye, Z. Zhou, H. Zou, Y. Shen, T. Xu, J. Tang, H. Yin, M. Chen, Y. Leng, and J. Shen, Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes, Bioorg. Med. Chem. 17 (2009), pp. 5722–5732.
   PubMed Web of Science ®Google Scholar
• M.M. Veniant, C. Hale, R.W. Hungate, K. Gahm, M.G. Emery, J. Jona, S. Joseph, J. Adams, A. Hague, G. Moniz, J. Zhang, M.D. Bartberger, V. Li, R. Syed, S. Jordan, R. Komorowski, M.M. Chen, R. Cupples, K.W. Kim, D.J. Jean, L. Johansson, M.A. Henriksson, M. Williams, J. Vallgarda, C. Fotsch, and M. Wang, Discovery of a potent, orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: Identification of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221), J. Med. Chem. 53 (2010), pp. 4481–4487.
   PubMed Web of Science ®Google Scholar
• J. Xiang, M. Ipek, V. Suri, W. Massefski, N. Pan, Y. Ge, M. Tam, Y. Xing, J.F. Tobin, X. Xuc, and S. Tama, Synthesis and biological evaluation of sulfonamidooxazoles and beta-keto sulfones: Selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I, Bioorg. Med. Chem. Lett. 15 (2005), pp. 2865–2869.
   PubMed Web of Science ®Google Scholar
• W. Sun, M. Maletic, S.S. Mundt, K. Shah, H. Zokian, K. Lyons, S.T. Waddell, and J. Balkovec, Substituted phenyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1, Bioorg. Med. Chem. Lett. 21 (2011), pp. 2141–2145.
   PubMed Web of Science ®Google Scholar
• M. Maletic, A. Leeman, M. Szymonifka, S.S. Mundt, H.J. Zokian, K. Shah, J. Dragovic, K. Lyons, R. Thieringer, A.H. Vosatka, J. Balkovec, and S.T. Waddell, Bicyclo[2.2.2]octyltriazole inhibitors of 11β-hydoxysteroid dehydrogenase type 1. Pharmacological agents for the treatment of metabolic syndrome, Bioorg. Med. Chem. Lett. 21 (2011), pp. 2568–2572.
   PubMed Web of Science ®Google Scholar
• P.R. Murumkar, R. Giridhar, and M.R. Yadav, 3D-quantitative structure-activity relationship studies on benzothiadiazepine hydroxamates as inhibitors of tumor necrosis factor-alpha converting enzyme, Chem. Biol. Drug Des. 71 (2008), pp. 363–373.
   PubMed Web of Science ®Google Scholar
• SYBYL Molecular modeling System, Version 7.0, 2003, Tripos Inc., 1699, South Hanley Road, St Louis, MO 63144, USA.
   Google Scholar
• L.D. Mendelsohm, ChemDraw 8 Ultra, Windows and Macintosh Versions, J. Chem. Inf. Mod. 44 (2004), pp. 2225–2226.
   Web of Science ®Google Scholar
• N.M. O’Boyle, M. Banck, C. James, C. Morley, Z. Vandermersch, and G.R. Hutchison, Open Babel: An open chemical toolbox, J. Cheminform. 3 (2011), pp. 33–36.
   PubMed Web of Science ®Google Scholar
• P.R. Murumkar, M.K. Sharma, A.C. Shinde, and K.G. Bothara, Three-dimensional quantitative structure–activity relationship CoMFA/CoMSIA on pyrrolidine-based tartrate diamides as TACE inhibitors, Med. Chem. Res. 22 (2013), pp. 4192–4201.
   Web of Science ®Google Scholar
• M.K. Sharma, P.R. Murumkar, R. Giridhar, and M.R. Yadav, Exploring structural requirements for peripherally acting 1,5-diaryl pyrazole-containing cannabinoid 1 receptor antagonists for the treatment of obesity, Mol. Divers. 19 (2015), pp. 871–893.
   PubMed Web of Science ®Google Scholar
• Glide 5.5, Schrodinger Inc. USA, 2009.
   Google Scholar
• V. Srivastava, S.P. Gupta, M.I. Siddiqi, and B.N. Mishra, 3D-QSAR studies on quinazoline antifolate thymidylate synthase inhibitors by CoMFA and CoMSIA models, Eur. J. Med. Chem. 45 (2010), pp. 1560–1571.
   PubMed Web of Science ®Google Scholar
• P.R. Murumkar, S. DasGupta, V.P. Zambre, R. Giridhar, and M.R. Yadav, Development of predictive 3D-QSAR CoMFA and CoMSIA models for beta-aminohydroxamic acid-derived tumor necrosis factor-alpha converting enzyme inhibitors, Chem. Biol. Drug Des. 73 (2009), pp. 97–107.
   PubMed Web of Science ®Google Scholar
• P.R, Murumkar, V.P. Zambre, and M.R. Yadav, Development of predictive pharmacophore model for in silico screening, and 3D QSAR CoMFA and CoMSIA studies for lead optimization, for designing of potent tumor necrosis factor alpha converting enzyme inhibitors, J. Comput. Aided Mol. Des. 24 (2010), pp. 143–156.
   PubMed Web of Science ®Google Scholar
• R.D. Cramer, D.E. Patterson, and J.D. Bunce, Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins, J. Am. Chem. Soc. 110 (1988), pp. 5959–5967.
   PubMed Web of Science ®Google Scholar
• P.R. Murumkar, L. Le, T.N. Truong, and M.R. Yadav, Determination of structural requirements of influenza neuraminidase type A inhibitors and binding interaction analysis with the active site of A/H1N1 by 3D-QSAR CoMFA and CoMSIA modeling, Med. Chem. Commun. 2 (2011), pp. 710–719.
   Web of Science ®Google Scholar
• P.R. Murumkar, M.K. Sharma, R. Giridhar, and M.R. Yadav, Virtual screening-based identification of lead molecules as selective TACE inhibitors, Med. Chem. Res. 24 (2015), pp. 226–244.
   Web of Science ®Google Scholar
• X. Wu, S. Wan, Z. Li, L. Yang, J. Zhang, and S. Wu, 3D-QSAR study on 2,3-dihydroimidazo[4,5]-pyridin-2-one derivatives with a meta substitution pattern as V600EBRAF inhibitors, Med. Chem. Res. 23 (2014), pp. 587–602.
   Web of Science ®Google Scholar
• G. Kliebe, U. Abraham, and T. Mietzner, Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity, J. Med. Chem. 37 (1994), pp. 4130–4146.
   PubMed Web of Science ®Google Scholar
• S. Durdagi, A. Kapou, T. Kourouli, T. Andreou, S.P. Nikas, V.R. Nahmias, D.P. Papahatjis, M.G. Papadopoulos, and T. Mavromoustakos, The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1′ position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2, J. Med. Chem. 5 (2007), pp. 2875–2885.
   Web of Science ®Google Scholar
• V.P. Zambre, P.R. Murumkar, R. Giridhar, and M.R. Yadav, Structural investigations of acridine derivatives by CoMFA and CoMSIA reveal novel insight into their structures toward DNA G-quadruplex mediated telomerase inhibition and offer a highly predictive 3D-model for substituted acridines, J. Chem. Inf. Model. 49 (2009), pp. 1298–1311.
   PubMed Web of Science ®Google Scholar
• V.P. Zambre, P.R. Murumkar, R. Giridhar, and M.R. Yadav, Development of highly predictive 3D-QSAR CoMSIA models for anthraquinone and acridone derivatives as telomerase inhibitors targeting G-quadruplex DNA telomere, J. Mol. Graph. Model. 29 (2010), pp. 229–239.
   PubMed Web of Science ®Google Scholar
• R.D. Cramer, J.D. Bunce, and D.E. Patterson, Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies, Quant. Struct-Act. Relat. 7 (1988), pp. 18–25.
   Web of Science ®Google Scholar
• S. Kamath and J.K. Buolamwini, Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors, J. Med. Chem. 46 (2003), pp. 4657–4668.
   PubMed Web of Science ®Google Scholar
• J. Perez-Villanueva, J.L. Medina-Franco, T.R. Caulfield, A. Hernandez-Campos, F. Hernandez-Luis, L. Yepez-Mulia, and R. Castillo, Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of some benzimidazole derivatives with trichomonicidal activity, Eur. J. Med. Chem. 46 (2011), pp. 3499–3508.
   PubMed Web of Science ®Google Scholar
• H. Abedi, H. Ebrahimzadeh, and J.B. Ghasemi, 3D-QSAR, CoMFA, and CoMSIA of new phenyloxazolidinones derivatives as potent HIV-1 protease inhibitors, Struct. Chem. 24 (2013), pp. 433–444.
   Web of Science ®Google Scholar
• S. Wold, Cross-validatory estimation of the number of components in factor and principal components models, Technometrics 20 (1978), pp. 397–405.
   Web of Science ®Google Scholar
• W.J. Dunn, S. Wold, V. Edlund, and S. Helberg, Multivariate structure-activity relationships between data from a battery of biological tests and an ensemble of structure descriptors: The PLS method, Quant. Struct-Act Relat. 3 (1984), pp. 131–137.
   Google Scholar
• M.K. Sharma, P.R. Murumkar, G. Kuang, Y. Tang, and M. Ram Yadav, Identifying the structural features and diversifying the chemical domain of peripherally acting CB1 receptor antagonists using molecular modeling techniques, RSC Adv. 6 (2016), pp. 1466–1483.
   Web of Science ®Google Scholar
• H. Yamaguchi, T. Akitaya, T. Yu, Y. Kidachi, K. Kamiie, T. Noshita, H. Umetsu, and K. Ryoyamak, Molecular docking and structural analysis of cofactor-protein interaction between NAD⁺ and 11β-hydroxysteroid dehydrogenase type 2, J. Mol. Model. 18 (2011), pp. 1037–1048.
   PubMed Web of Science ®Google Scholar
• Y. Liu, X. Lu, T. Xue, S. Hu, and H. Zhang, Receptor and ligand-based 3D-QSAR study on a series of pyrazines/pyrrolidylquinazolines as inhibitors of PDE10A enzyme, Med. Chem. Res. 23 (2014), pp. 775–789.
   Web of Science ®Google Scholar
• B. Sorensen, M. Winn, J. Rohde, Q. Shuai, J. Wang, S. Fung, K. Monzon, W. Chiou, D. Stolarik, H. Imade, L. Pan, X. Deng, L. Chovan, K. Longenecker, R. Judge, W. Qin, M. Brune, H. Camp, E.U. Frevert, P. Jacobson, and J.T. Link, Adamantane sulfone and sulfonamide 11-beta-HSD1 inhibitors, Bioorg. Med. Chem. Lett. 17 (2007), pp. 527–532.
   PubMed Web of Science ®Google Scholar
• H. Tu, J.P. Powers, J. Liu, S. Ursu, A. Sudom, X. Yan, H. Xu, D. Meininger, M. DeGraffenreid, X. He, J.C. Jaen, D. Sun, M. Labelle, H. Yamamoto, B. Shan, N.P.C. Walker, and Z. Wang, Distinctive molecular inhibition mechanisms for selective inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1, Bioorg. Med. Chem. 16 (2008), pp. 8922–8931.
   PubMed Web of Science ®Google Scholar